Skip to main content

bet bromodomain inhibitor zen-3694

Generic: BET Bromodomain Inhibitor ZEN-3694

bet bromodomain inhibitor zen-3694: 9 clinical trials tracked.

bet bromodomain inhibitor zen-3694 evidence translation

What we can confirm

9 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about bet bromodomain inhibitor zen-3694, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 5 study sponsors
Clinical Trials (9)

A Phase II Study of Sequential Bipolar Androgen Therapy and ZEN-3694 in Sequence With Enzalutamide + ZEN-3694 in Asymptomatic Patients With Metastatic CRPC: The COSMYC Trial (COmbined Suppression of MYC)

NCT06922318·Phase 2·KYNB
Recruiting

Primary endpoint: Clinical/radiographic progression free survival (PFS) with BATZEN

Interventionalopen50 targetStarted 2025-08Completion 2031-081 site · United StatesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination With Cetuximab and Encorafenib in Patients With Refractory BRAF V600E Metastatic Colorectal Cancer

NCT06102902·Phase 1·FATE
Recruiting

Primary endpoint: Maximum tolerated dose (dose escalation cohort)

Interventionalopen30 targetStarted 2024-06Completion 2027-0115 sites · United StatesNational Cancer Institute (NCI)

Phase I Trial of ZEN003694 (ZEN-3694) in Combination With Capecitabine in Patients With Solid Tumors

NCT05803382·Phase 1·MRUS
Recruiting

Primary endpoint: Incidence of adverse events

Interventionalopen30 targetStarted 2023-11Completion 2026-0622 sites · United StatesNational Cancer Institute (NCI)

A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer

NCT05422794·Phase 1·ENTA
Recruiting

Primary endpoint: Maximum tolerated dose (MTD) of ZEN003694 (ZEN-3694) used in combination with pembrolizumab and nab-paclitaxel

Interventionalopen57 targetStarted 2023-05Completion 2027-036 sites · United StatesNational Cancer Institute (NCI)

Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer

NCT05071937·Phase 2
Recruiting

Primary endpoint: Objective Response

Interventionalopen33 targetStarted 2023-04Completion 2034-121 site · United StatesAlexander B Olawaiye, MD

A Phase 1 Study of ZEN003694 in Combination With Binimetinib in Solid Tumors With RAS Pathway Alterations and Triple Negative Breast Cancer

NCT05111561·Phase 1·RLAY
Suspended

Primary endpoint: Incidence of dose limiting toxicities (Part 1 [Dose Escalation])

Interventionalopen42 targetStarted 2022-08Completion 2027-034 sites · United StatesNational Cancer Institute (NCI)

A Phase 1 Study of the Bromodomain Inhibitor ZEN003694 in Combination With Platinum-based Chemotherapy in Patients With NUT Carcinoma

NCT05019716·Phase 1·MRUS
Recruiting

Primary endpoint: Maximum tolerated dose (MTD) (phase 1)

Interventionalopen36 targetStarted 2022-07Completion 2026-065 sites · United StatesNational Cancer Institute (NCI)

A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

NCT04471974·Phase 2
Active, not recruiting

Primary endpoint: Composite Response Rate

Interventionalopen61 enrolledStarted 2021-01Completion 2028-053 sites · United StatesRahul Aggarwal

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

NCT04145375·Phase 1·KYNB
Enrolling by invitation

Primary endpoint: Incidence of treatment-related adverse events (AE) and treatment-related serious adverse events (SAE)

Interventionalopen40 targetStarted 2019-11Completion 2026-122 sites · United StatesZenith Epigenetics